Crossmark

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Crossref DOI link: https://doi.org/10.1186/s13075-017-1462-2

Published Online: 2017-11-22

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Horneff, Gerd https://orcid.org/0000-0001-5491-7832
Schulz, Anna Carina

Klotsche, Jens

Hospach, Anton

Minden, Kirsten

Foeldvari, Ivan

Trauzeddel, Ralf

Ganser, Gerd

Weller-Heinemann, Frank

Haas, Johannes Perter
Funding

Funding for this research was provided by:

Novartis Pharma

Chugai Pharmaceutical

F. Hoffmann-La Roche

Pfizer UK